Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ATLAS Biolabs is Awarded Certified Service Provider Accreditation from Affymetrix for DMET Analysis

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity.

ATLAS Biolabs announces its accreditation as a certified Affymetrix DMET™ Service Provider, offering the latest DMET™ Plus Solution from Affymetrix. ATLAS Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.

Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolizing enzymes and drug transporters. Analyzing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.

DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimization of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.

“DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalized medicine,” says Patrick Kelly, Director of Sales and Market Development at ATLAS Biolabs. “We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way.”

The DMET™ Plus Solution
DMET Plus from Affymetrix includes (a) a molecular inversion probe (MIP) panel to amplify the precise target DNA of interest; (b) an allele-specific oligonucleotide array providing a single-color readout on Affymetrix’s GeneChip System® 3000 or the GeneChip® System 3000Dx v.2; and (c) the DMET analysis software, which offers both flexibility for user-defined reporting and the most comprehensive translation from genotypic data to star-allele classification and to predicted metabolizer status for the most clinically relevant genes. Assay performance is characterized by >99% average sample-call rates and >99.8% average sample reproducibility, which enables the accurate generation of haplotypes and supports longitudinal and other clinical research studies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos